Mimi I. Hu, M.D.
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
About Dr. Mimi I. Hu
Dr. Mimi I. Hu graduated from Rice University with a degree in mechanical engineering. She obtained her medical degree from the University of Texas - Houston Health Sciences Center. She completed her residency and endocrine fellowship at the Baylor College of Medicine, where she also served as chief medical resident. After completion of her research fellowship at MD Anderson, she joined the faculty in 2007 in the department of Endocrine Neoplasia and Hormonal Disorders. Dr. Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma (differentiated and medullary), hereditary endocrine neoplasia disorders and metabolic bone and mineral disorders. Her research interests include investigating novel therapeutics for advanced thyroid cancer and understanding and overcoming resistance mechanisms. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders.
Present Title & Affiliation
Primary Appointment
Professor, Endocrine Neoplasia and Hormonal Disorders, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas
Clinical Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston, Texas
Education & Training
Degree-Granting Education
| 2000 | University of Texas Houston Health Science Center, Houston, Texas, US, MD |
| 1993 | Rice University, Houston, Texas, US, BS in Mechanical Engineering |
Postgraduate Training
| 2009-2009 | Faculty Development, Heart of Leadership, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2008 | Clinical Research Curriculum, University of Texas-Houston Medical School, Houston, Texas |
| 2004-2007 | Fellowship, Endocrinology, Baylor College of Medicine, Houston, Texas |
| 2000-2003 | Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2023 | Georgia Medical Board |
| 2023 | Oklahoma State Board of Medical Licensure & Supervision |
| 2023 | Arizona Medical Board |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Louisiana Medical Board |
| 2023 | Alabama Board of Medical Examiners |
| 2023 | Washington Medical Commission |
| 2021 | Florida Board of Medicine |
| 2006 | Endocrinology, Diabetes and Metabolism |
| 2004 | Internal Medicine |
| 2002 | Texas Medical Board |
Experience & Service
Administrative Appointments/Responsibilities
Deputy Department Chair, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - Present
Fellowship Program Director, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011 - Present
Member, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2008 - Present
Other Professional Positions
Member, Medullary Thyroid Cancer Registry Steering Committee, Houston, Texas, 2018 - Present
Research Assistant, University of Texas Houston Medical School, Houston, Texas, 1997 - Present
Intramural Institutional Committee Activities
Member, Endocrine Center Shared Governance Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Ascending Senior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Scientific Review Committee (SRC) #1, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Texas Medical Board Approved Programs Liaison, Graduate Medical Education Executive Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2021
Member, Search Committee for Chair of Head and Neck Surgery Department, The University of Texas MD Anderson Cancer Center, 2017 - 2017
Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2016 - 2019
Member, Search Committee for Section Chief of Head and Neck Endocrine Surgery, The University of Texas MD Anderson Cancer Center, 2016 - 2016
Chair, Clinical Operations Committee in Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2016 - 2020
Member, Department of Endocrine Neoplasia and Hormonal Disorders Executive Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Endocrine Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2021
Chair, Clinical Faculty Search Committee for Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 2014 - 2015
Division Representative, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Clinical Research Committee 3, The University of Texas MD Anderson Cancer Center, 2011 - 2012
Member, Pharmacy & Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2016
Member, Clinical Research Committee 4, The University of Texas MD Anderson Cancer Center, 2010 - 2011
Member, Multidisciplinary Bone Health Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2016
Member, Editorial Board for Department Publications and Website Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2016
Member, Endocrine Center Steering Committee for the Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, 2008 - 2010
Member, Clinical Research Committee 2, The University of Texas MD Anderson Cancer Center, 2008 - 2010
Member, Graduate Medical Education Budget Subcommittee, The University of Texas MD Anderson Cancer Center, 2008 - Present
Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2013
Extramural Institutional Committee Activities
Member, IMC Lean Initiative, The University of Texas MD Anderson Cancer Center, 2007 - 2008
Editorial Activities
Section Editor - MEN2 Topics, UpToDate (Endocrinology & Diabetes Content), 2022 - Present
Honors & Awards
| 2025 | Top 1% Provider in the Nation, ThyCa: Thyroid Cancer Survivors’ Association |
| 2023 - 2024 | GME Program Director Award, The University of Texas MD Anderson Cancer Center |
| 2023 | ATA's Galton Distinguished Lectureship Award, American Thyroid Association |
| 2022 | Nomination for Division of Internal Medicine Excellence in Patient Care |
| 2021 | DoIM Distinguished Paper Award for Clinical Research (Jan - Jun 2021 Period), MDACC Division of Internal Medicine |
| 2021 | DoIM Distinguished Paper Award for Clinical Research (July - December 2021 Period), MDACC Division of Internal Medicine |
| 2020 | Nomination for the Division of Internal Medicine Excellence Award - Excellence in Education |
| 2019 - 2025 | Exceptional Woman in Medicine, Castle Connolly |
| 2018 | 2018 Faculty Excellence in Education & Mentorship Advancement, The University of Texas MD Anderson Cancer Center |
| 2017 - 2018 | Best Doctors in America, Best Doctors |
| 2017 | Nomination for Department of Education Outstanding GME Program Director Award, The University of Texas MD Anderson Cancer Center |
| 2016 - 2017 | Faculty Leadership Academy (Cohort 16), The University of Texas MD Anderson Cancer Center |
| 2015 | ENDO 2015 Outstanding Abstract Award and Presidential Poster Competition Finalist, Endocrine Society 97th Annual Meeting |
| 2014 - 2025 | Top Doctors in America, Castle Connolly |
| 2014 | Faculty Educator of the Month - May 2014, MD Anderson Cancer Center |
| 2011 - 2012 | U.S. News Top Doctors, U.S. News and World Report, Castle Connolly Medical Ltd |
| 2011 | ENDO 2011 Outstanding Abstract Award and Presidential Poster Competition Finalist, Endocrine Society 93rd Annual Meeting |
| 2009 | Heart of Leadership, The University of Texas MD Anderson Cancer Center |
| 2006 | Travel Grant Award for Young Investigators, American Thyroid Association 77th Annual Meeting |
| 1999 | Alpha Omega Alpha Honor Society |
| 1998 | Chinese American Doctors Association of Houston Scholarship |
| 1997 - 2000 | Lucy Massenburg Scholarship, University of Texas Houston Health Sciences Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Systemic Therapy for Advance, Progressive Medullary Thyroid Carcinoma. Conference. Endocrine Fellows Foundation Onco-Endocrinology, Echo Program-Virtual. Houston, Texas, US.
- 2025. Thyroid Cancer, 2025. Conference. Comprehensive Board Review in Hematology and Medical Oncology-Virtual. Houston, Texas, US.
- 2024. Thyroid Cancer, 2024. Conference. Hematology and Medical Oncology Board Review-Virtual. Houston, Texas, US.
Regional Presentations
- 2025. Medullary Thyroid Carcinoma. Invited. AACE Endocrine University- Virtual, US.
- 2025. Multiple Endocrine Neoplasia, Type 1: What's New in the 2025 Consensus Statement and Guidelines for Best Practice?. Invited. 2025 Annual Meeting of Michigan Association of Endocrinologists. Dearborn, Michigan, US.
- 2024. The Role of Imaging in the Management of Differentiated Thyroid Carcinoma. Conference. Annual Meeting of AACE. New Orleans, Louisiana, US.
- 2024. Session II: Differentiated Thyroid Cancer. Invited. ITOG 2024 Annual Meeting. Ponte Verde, Florida, US.
- 2024. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University-Virtual, US.
National Presentations
- 2026. CTRET-Mutated Medullary Thyroid Cancer Symposium. Invited. ENDO 2026. Washington, District of Columbia, US.
- 2026. Dissecting the Role of RET in Thyroid Cancer. Invited. ENDO 2026. Washington, District of Columbia, US.
- 2025. RET Inhibitors in Medullary Thyroid Carcinoma-Podcast. OnlineOnly. Podcast-Interviewed by Desai K Medscape, US.
- 2025. Medullary Thyroid Carcinoma: What Every Patient and Caregiver Should Know About It. Invited. 28th International Thyroid Cancer Survivors Conference. Houston, TX, US.
- 2025. Medullary Thyroid Carcinoma: The Spectrum of Treatments. Invited. 28th International Thyroid Cancer Survivors Conference. Houston, Tx, US.
- 2025. Sequencing Systemic Therapies in Medullary Thyroid Carcinoma. Invited. 94th Annual Meeting of the American Thyroid Association. Scottsdale, Arizona, US.
- 2025. Targeted Therapies for Advance Thyroid Cancer. Conference. WCTC 2025. Boston, Massachusetts, US.
- 2025. Developing a Career in Thyroid Cancer: Insight from Endocrinologist, Oncologists, and Surgeons. Panelist. WCTC 2025. Boston, Massachusetts, US.
- 2025. Advances in the Treatment of Medullary Thyroid Carcinoma. Conference. SPED Puerto Rico, US.
- 2025. Fundamentals of Thyroid Cancer. Conference. AACE Endocrine University-Virtual, US.
- 2024. Medullary Thyroid Carcinoma. Conference. AACE Endocrine University, American Association of Clinical Endocrinologists. virtual, US.
- 2024. ATA Guidelines Update: Medullary Thyroid Cancer – Systemic Therapies. Conference. 93rd Annual Meeting of the American Thyroid Association American Thyroid Association. Chicago, IIllinois, US.
- 2024. Medullary Thyroid Carcinoma: What Every Patient and Caregiver Should Know About It,. Conference. 27th International Thyroid Cancer Survivors' Conference. Houston, Texas, US.
- 2024. Medullary Thyroid Carcinoma: The Spectrum of Treatments. Conference. 27th International Thyroid Cancer Survivors' Conference. Houston, Texas, US.
International Presentations
- 2026. Emergent peripheral vascular disease (PVD) in medullary thyroid carcinoma (MTC) patients treated with pralsetinib: a case series. Poster. European Thyroid Association (ETA). Porto, PT.
- 2025. Acquired Resistance to RET- Inhibitors in Medullary Thyroid Carcinoma- Virtual. Invited. ITOG Educational Program Webinar, US.
- 2025. Advances in the Treatment of Medullary Thyroid Carcinoma. Conference. 17th International Thyroid Congress. Rio de Janeiro, BR.
- 2025. American Thyroid Association's Guidelines Update: Medullary Thyroid Cancer Systemic Therapies. Conference. 19th International World Men Workshop. Sao Paulo, BR.
- 2025. Severe Peripheral Vascular Disease in Patients Treated with Pralsetinib. Conference. ITOG 2025 Annual Meeting. Ann Arbor, US.
- 2025. Metabolic Bone Disease. Conference. Medical Education Resources. Montego Bay, JM.
- 2025. Endocrinology Cases: Calcium Disorders and Osteoporosis. Conference. Montego Bay, JM.
- 2025. Disorders of Calcium Metabolism. Conference. Medical Education Resources. Montego Bay, JM.
- 2025. Osteoporosis: Diagnosis and Treatment. Conference. Medical Education Resources. Montego Bay, JM.
- 2024. Medullary Thyroid Carcinoma: Updates on Evaluation and Management. Invited. CODHy. Shanghai, CN.
Formal Peers
- 2025. An Update on the Evaluation and Management of Medullary Thyroid Carcinoma. Houston, Texas, US.
- 2024. Update on Management of Advanced Medullary Thyroid Carcinoma. London, UK, GB.
- 2024. Update on Management of Advanced Medullary Thyroid Carcinoma. Farmington, CT, US.
- 2024. Advanced Thyroid Cancer: Management Beyond Surgery and RAI. Tampa, FL, US.
- 2024. Medullary Thyroid Carcinoma: Updates on Evaluation and Management, US.
- 2023. Update on the Management of Advanced Thyroid Cancer, US.
- 2023. Advanced Thyroid Cancer Management Beyond RAI, US.
- 2023. Medullary Thyroid Carcinoma: Systemic Treatments and Management. Invited. Virtual, MI, US.
- 2023. Advanced Thyroid Cancer: Targetable Mutations and Spectrum of Therapeutics. Invited. Virtual, RI, US.
- 2023. Medullary Thyroid Carcinoma: Update on Evaluation and Management. Invited. Virtual, CA, US.
- 2022. Update on Medullary Thyroid Carcinoma. Invited. Virtual, NJ, US.
- 2022. Thyroid Cancer. Invited. Houston, TX, US.
- 2021. Medullary Thyroid Carcinoma. Invited. Stony Brook (Virtual), NY, US.
- 2021. Medullary Thyroid Carcinoma. Invited. Palo Alto (Virtual), CA, US.
- 2020. Medullary Thyroid Carcinoma and MEN2 Syndromes. Invited, NJ, US.
- 2020. Overview of Driver Genes in Differentiated and Medullary Thyroid Cancer and Update on RET-Inhibitors. Invited, US.
- 2020. Overview of Driver Genes in Differentiated and Medullary Thyroid Cancer and Update on RET-Inhibitors. Invited. Sao Paulo, BR.
- 2020. Differentiated Thyroid Cancer: Overview and Spectrum of Treatments. Invited, CA, US.
- 2020. Advanced Thyroid Cancer: Update on Treatments Based on Driver Mutations. Invited. Phoenix, AZ, US.
- 2019. Medullary thyroid cancer and treatment landscape for this rare disease. Invited, US.
- 2019. Medullary Thyroid Cancer: Review and Update on New Therapeutic Options for Advanced Disease. Invited. Rochester, NY, US.
- 2019. Medullary Thyroid Carcinoma: Update on Systemic Therapies. Invited. Houston, TX, US.
- 2019. Cancer-Related Bone Loss and Management. Invited. Philadelphia, PA, US.
- 2018. Medullary Thyroid Cancer Clinic Day. Invited. Bethesda, MD, US.
- 2018. Medical management of medullary thyroid carcinoma. Invited. Rome, IT.
- 2017. Medullary Thyroid Carcinoma. Invited. East Providence, RI, US.
- 2017. Oncologic Endocrinology: Evolution of a Super-Specialty. Invited. Houston, TX, US.
- 2014. Cancer: Bad to the Bone. Invited. Nashville, TN, US.
- 2007. Postoperative hypoparathyroidism and the role of short-term teriparatide therapy. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2019 - 2023 |
| Title: | A novel natural history study of medullary thyroid carcinoma: Incorporating the patient perspective to inform advanced disease management |
| Funding Source: | Food and Drug Administration (FDA) |
| Role: | Collaborator |
| ID: | 1R01FD006650-01 |
Selected Publications
Peer-Reviewed Articles
- Cabanillas ME, Busaidy N, Zafereo M, Iyer PC, Wang JR, Hamidi S, Ferrarotto R, Liu S, Gunn GB, Spiotto M, Lee A, Maniakas A, Gule-Monroe M, Williams MD, Hosseini SM, Banuchi VE, Hu MI, Ning M, Dadu R. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial 246(117013), 2026. e-Pub 2026. PMID: 42673705.
- Marczyk, VR, Wu, C, Hamidi, S, Li, S, Loberg, MA, Martin, M, Williams, MD, Hosseini, SM, Waguespack, SG, Hu, MI, Sherman, SI, Henderson, Y, Lai, SY, Dai, Y, Wang, W, Maniakas, A, Zafereo, M, Sheng, Q, Xu, GJ, Huang, EC, Weiss, VL, Cabanillas, ME, Wang, RJ. Revised Thyroid Differentiation Score for Risk Stratification in Papillary Thyroid Carcinoma. JCO Precision Oncology 10(7), 2026. e-Pub 2026. PMID: 42492028.
- Salim, H, Learned, KO, Zafereo, M, Wang, RJ, Msherghi, A, Dagher, SA, Taslicay, CA, Al Qudah, H, Alizada, S, Hu, MI, Cabanillas, ME, Busaidy, NL, Hamidi, S, Tawbi, H, Eldaya, R, Li, J, Wintermark, M. Whole-Brain Radiation Therapy for Brain Metastases due to Thyroid Cancer. Clinical Oncology 52, 2026. e-Pub 2026. PMID: 41780125.
- Salim, H, Agosto, S, Al Qudah, H, Learned, KO, Zafereo, M, Wang, RJ, Hu, MI, Msherghi, A, Busaidy, NL, Ucisik, FE, Hamidi, S, Tawbi, H, Eldaya, R, Li, J, Wintermark, M, Cabanillas, ME. A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases. Journal of neuro-oncology 177(2), 2026. e-Pub 2026. PMID: 41981321.
- Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A,, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series with Operative Techniques. Head & Neck. Head & Neck 48(2):E20-E24, 2026. e-Pub 2026. PMID: 40747656.
- Onuma, AE, Skefos, CM, Richardson, ME, Pasyar, S, Fergus, KB, Bassett Jr, R, Hu, MI, Perrier, ND, Maniakas, A, Zafereo, M, Waguespack, SG, Sosa, JA, Grubbs, EG. The shifting landscape of germline RET pathogenic variants with the introduction of panel testing. Surgery (United States) 189, 2026. e-Pub 2026. PMID: 41371824.
- Fournier I, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head Neck 48(1):237-245, 2026. e-Pub 2026. PMID: 40891104.
- Brinkman AK, Salami-Henry AY, Aaron-Brija LA, Hannah FM, Hu MI, Hwang LL, Patel RP, Rollins JL, Sherman SI, Williams JK, Kikani NJ, Weitzman SP. Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid Dysfunction. JCO Oncol Pract 19:OP2500440, 2025. e-Pub 2025. PMID: 41418091.
- Maniakas A, Wilde DC, Fournier I, Hyde EK, Xu L, Wang JR, Gross ND, Sturgis EM, Banuchi V, Busaidy NL, Cabanillas ME, Iyer P, Dadu R, Waguespack SG, Hu MI, Gunn GB, Kwon M, Ahmed S, Williams MD, Zafereo ME. Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival. Head Neck 48(3):644-649, 2025. e-Pub 2025. PMID: 41059669.
- Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, Hu MI, Ge MH, Wadsley J, Vaisman F, Kopeckova K, Krajewska J, Olvera D, Churchill C, Maeda P, Gilligan AM, Lin Y, Payakachat N, Robinson B, Hadoux J, Brose MS. Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer. Thyroid 35(10):1162-1172, 2025. e-Pub 2025. PMID: 40828665.
- Shariq, O, Waguespack, SG, Hamidi, S, Kensing, BC, Hu, MI, Skefos, CM, Perrier, ND. Approach to the Patient: Hereditary Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism 110(9):2685-2697, 2025. e-Pub 2025. PMID: 40105880.
- Deschler-Baier, B, Konda, B, Massarelli, E, Hu, MI, Wirth, L, Xu, X, Wright, J, Clifton-Bligh, RJ. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 110(3):e600-e606, 2025. e-Pub 2025. PMID: 38661071.
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
- Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2024. e-Pub 2024. PMID: 39662038.
- Hensley, SG, Hu, MI, Bassett Jr, R, Ying, AK, Zafereo, M, Perrier, ND, Busaidy, NL, Hyde, S, Grubbs, EG, Waguespack, SG. Pediatric Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism 109(9):2256-2268, 2024. e-Pub 2024. PMID: 38441533.
- Sarah Hamidi, Armeen Mahvash, Hu MI. Paraneoplastic Diarrhea from Medullary Thyroid Carcinoma Resolved with Yttrium-90 Radioembolization of Liver Metastases. JCEM Case Rep 2(8):103, 2024. e-Pub 2024. PMID: 39076377.
- Shirali, AS, Hu, MI, Chiang, YJ, Graham, PH, Fisher, SB, Sosa, JA, Perrier, ND, Brown, S, Holla, V, Dadu, R, Busaidy, NL, Sherman, SI, Cabanillas, ME, Waguespack, SG, Zafereo, M, Grubbs, EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients. Journal of the Endocrine Society 8(6), 2024. e-Pub 2024. PMID: 38660141.
- Maniakas, A, Sullivan, A, Hu, MI, Busaidy, NL, Cabanillas, ME, Dadu, R, Waguespack, SG, Fisher, SB, Graham, PH, Gross, N, Grubbs, EG, Perrier, ND, Wang, RJ, Gunn, GB, Garden, AS, Megahed, R, Navuluri, S, Li, X, Williams, MD, Zafereo, M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head and Neck 46(2):328-335, 2024. e-Pub 2024. PMID: 38009416.
- Subbiah V*, Hu MI*, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alongso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzman S, Brose MS. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid 34(1):26-40, 2024. e-Pub 2024. PMID: 38009200.
- Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ, LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. New England Journal of Medicine 389(20):1851-1861, 2023. e-Pub 2023. PMID: 37870969.
- El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 108(3):507-528, 2023. e-Pub 2023. PMID: 36545746.
- Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 33(1):129-132, 2023. e-Pub 2023. PMID: 36503246.
- Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer. Oral Dis 28(1):193-201, 2022. e-Pub 2022. PMID: 33274559.
- Hu MI, Subbiah V, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW). Lancet Diabetes Endocrinol 9(8):491-501, 2021. e-Pub 2021. PMID: 34118198.
- Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. J Clin Endocrinol Metab 106(8):2198-2207, 2021. e-Pub 2021. PMID: 34009369.
- Shojaie D, Hoffman AS, Amaku R, Cabanillas ME, Sosa JA, Waguespack SG, Zafereo ME, Hu MI, Grubbs EE. Decision making when cancer becomes chronic. JMIR Form Res 5(7):e27484, 2021. e-Pub 2021. PMID: 34269691.
- Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis. Endocr Relat Cancer 28(7):419-31, 2021. e-Pub 2021. PMID: 33890870.
- Subbiah, V, Shen, T, Terzyan, SS, Liu, X, Hu, X, Patel, KP, Hu, MI, Cabanillas, ME, Amini, B, Meric-Bernstam, F, Vo, PT, Mooers, BH, Wu, J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Annals of Oncology 32(2):261-268, 2021. e-Pub 2021. PMID: 33161056.
- Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head and Neck 43(1):E7-E12, 2021. e-Pub 2021. PMID: 33169506.
Invited Articles
- Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am 50(4):721-728, 2021. e-Pub 2021. PMID: 34774243.
Review Articles
- Salim HA, Agosto S, Al Qudah H, Learned K, Zafereo M, Wang J, Hu MI, Msherghi A, Busaidy N, Ucisik FE, Hamidi S, Eldaya RW, Li J, Cabanillas ME, Wintermark M. A Differentiated Thyroid Carcinoma-Specific Graded Prognostic Assessment for Brain Metastases;. J Neurooncol Derivation(10):306, 2026. e-Pub 2026. PMID: 41981321.
- Hamidi Sarah, Maniakas Anastasios, Akhave Neal S., Banuchi Victoria E., Busaidy Naifa L., Dadu Ramona, Ferrarotto Renata, Guise Theresa A., Hofmann Marie-Claude, Hosseini S. Mohsen, Hu MI, Iyer Priyanka C., Mansour Mena, Marczyk Vicente R., Chowdhuri Sinchita Roy-, Sherman Steven I., Sousa Luana G., Wang Jennifer R., Williams Michelle D., Zafereo Mark E., Waguespack Steven G., Cabanillas Maria E.. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. The Journal of Clinical Endocrinology & Metabolism 111(2):471-483, 2026. e-Pub 2026. PMID: 40568752.
- Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, Sherman SI, Hamidi S, Hosseini SM, Williams MD, Ahmed S, Routbort MJ, Luthra R, Roy-Chowdhuri S, San Lucas FA, Patel KP, Hong DS, Zafereo M, Wang JR, Maniakas A, Waguespack SG, E Cabanillas M. NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. NTRK Fusion 9(2025):12, 2025. e-Pub 2025. PMID: 39983078.
- Hamidi, S, Hu, MI. RET kinase inhibitors for the treatment of RET-altered thyroid cancers. Annales d'endocrinologie 85(2):118-126, 2024. e-Pub 2024. PMID: 38342224.
- Vivek Subbiah, Mohamed A Gouda, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Luz E Castellanos, Hu MI, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu. Adaptive Darwinian Off-Target Resistance Mechanisms to Selective RET Inhibition in RET Driven Cancer 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
- Nardo, M, Gouda, MA, Nelson, BE, Barreto, CN, Slade, JH, Poullard, A, Zafereo, M, Hu, MI, Cabanillas, ME, Subbiah, V. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Reports Medicine 4(12), 2023. e-Pub 2023. PMID: 38118420.
- Cabanillas, ME, Iyer, PC, Hu, MI. A Decade of Progress in Targeted Therapy for Advanced Thyroid Cancer. Endocrine Practice 29(3):221-227, 2023. e-Pub 2023. PMID: 35756966.
- Hamidi, S, Hofmann, M, Iyer, PC, Cabanillas, ME, Hu, MI, Busaidy, NL, Dadu, R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Frontiers in Endocrinology 14, 2023. e-Pub 2023. PMID: 37435488.
- Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531. Future Oncol 18(28):3143-3150, 2022. e-Pub 2022. PMID: 35969032.
- Vodopivec DM, Hu MI. RET kinase inhibitors for RET-altered thyroid cancers. Ther Adv Med Oncol 14:17588359221101691, 2022. e-Pub 2022. PMID: 35756966.
- Jara MA, Varghese J, Hu MI. Adverse Events Associated with Bone-Directed Therapies in Patients with Cancer. Bone 158:115901, 2022. e-Pub 2022. PMID: 33631354.
Professional Educational Materials
- Tannock LR, Boelaert K, Carranza Leon BG, Clement S, Dahir KM, Donner TW, Freel M, Hu M, Irwig MS, Jonklaas J, Magill S, Reddy D, Salvatori R, Subramanian S, Vaidya A, Welt C. ESAP 2018: Endocrine Self-Assessment Program. Endocrine Society, 2018.
- Tannock LR, Boelaert K, Collazo-Clavell ML, Dahir KM, Dalkin AC, Donner TW, Freel M, Green J, Hu M, Irwig MS, Jonklaas J, Magill S, Mather K, Subramanian S, Tritos NA, Welt C. ESAP 2017: Endocrine Self-Assessment Program. Endocrine Society, 2017.
- Hu, Mimi. Medullary thyroid cancer. Thyroid Cancer Survivors' Association, Inc, 2014.
- Hu MI. Parathyroid cancer. Phyllis Pittman Communications Ltd, 2013.
- Hu MI. Bone health, 2012.
Other Articles
- Salim HA, Msherghi A, Learned K, Zafereo M, Wang J, Dagher SA, Altintas Taslicay C, Dagher R, Alizada S, Hu MI, Cabanillas ME, Busaidy N, Hamidi S, Tawbi H, Li J, Ucisik FE, Wintermark M Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Thyroid 35(12):1378-1390, 2025. PMID: 40956665.
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME Erratum. JCO Precision Oncology 9, 2025. PMID: 40632979.
Abstracts
- Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Sherman EJ, Tahara M, Hu MI, Lin Y, Maeda P, Wirth LJ, Capdevila J. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer. Annals of Oncology 34(S2):S187-S1060, 2023. e-Pub 2023.
- Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Sherman EJ, Tahara M, Hu MI, Lin Y, Maeda P, Wirth LJ, Capdevila J. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer. ESMO Congress 2023 34(S2):S187-S1060, 2023. e-Pub 2023.
- Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Fuhrer D, Keam B, Sherman EJ, Tahara M, Hu MI, Lin Y, Maeda P, Wirth LJ, Capdevila J. Randomized Phase III Study of Selpercatinib Versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer (Late Breaking Abstract 3 - Presidental Symposium. Annals of Oncology 34(S2), 2023. e-Pub 2023.
- Yamashita TS, Mulder M, Williams-Perez S, Cortell A, Huang CY, Zhao H, Peterson SK, Hu MI, Zafereo M, Gosness J, Sosa JA, Grubbs EG. The Multi-institutional Medullary Thyroid Cancer Collaborative Registry (MTCCoRe): Can a rare tumor registry accurately represent all affected patients?. Thyroid 33(S1):Poster 447, 2023. e-Pub 2023.
- Ning M, Dudzinski SO, Busaidy NL, Dadu R, Welsh J, Hu MI, Gunn B, Wang C, Waguespack SG, Phan J, Beckham TH, Chang JY, Sherman SI, Reddy JP, Ying AK, Oreilly M, Chen A, Lee A, Gandhi SN, Liao Z, Ludmir EB, Nguyen Q, Tang C, Lin SH, Zafereo MA, Cabanillas ME. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Feasible Strategy to Defer Escalation of Systemic Therapy. Thyroid 33(S1):Late Breaking Poster 543, 2023. e-Pub 2023.
- Yamashita TS, Mulder M, Williams-Perez S, Cortell A, Huang CY, Zhao H, Peterson SK, Hu MI, Zafereo M, Gosness J, Sosa JA, Grubbs EG. The Multi-institutional Medullary Thyroid Cancer Collaborative Registry (MTCCoRe): Can a rare tumor registry accurately (Poster 447. Thyroid 33(S1), 2023. e-Pub 2023.
- Ning M, Dudzinski SO, Busaidy NL, Dadu R, Welsh J, Hu MI, Gunn B, Wang C, Waguespack SG, Phan J, Beckham TH, Chang JY, Sherman SI, Reddy JP, Ying AK, Oreilly M, Chen A, Lee A, Gandhi SN, Liao Z, Ludmir EB, Nguyen Q, Tang C, Lin SH, Zafereo MA, Cabanillas ME. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Feasible Strategy to Defer Escalation of Systemic Therapy (Late Breaking Poster 543). Thyroid 33(S1), 2023. e-Pub 2023.
- Hu MI, Subbiah V, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth LJ, Garralda E, Adkins D, Godbert Y, Ahn MJ, Cassier P, Cho BC, Lin CC, Barata T, Zalutskaya A, Scalori A, Brose MS. Updated ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
- Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier ND, Brown S, Subbiah V, Holla VR, Dadu R, Busaidy NL, Sherman SI, Cabanillas ME, Waguespack SG, Zafereo M, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Evaluating the Relationship Between Somatic Alteration Profile and Disease Aggressiveness. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
- Hadoux J, Hu MI, Brose MS, Garralda E, Spitzweg C, Reguart N, Cao CD, Forster MD, Gordoa TA, Barata T, Scalori A, Zalutskaya A, Trask P, Subbiah V. Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive TC treated with pralsetinib in the ARROW trial. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
- Fazeli S, McBeath E, Gule-Monroe M, Cabanillas ME, Busaidy N, Waguespack SG, Hu MI, Jimenez C, Sherman SI, Habra MA, Cote GJ, Bassett R, Williams MD, Hofmann MC, Dadu R. BRAF +/- MEK Inhibitor Therapy in BRAF V600E-Mutated Differentiated Thyroid Carcinoma: Does the Presence of a TERT Promoter Mutation Influence Therapeutic Response?. Thyroid 32(S1):P-1-A-188, 2022. e-Pub 2022.
- Vodopivec DM, Chen YH, Cabanillas ME, Hu MI, Busaidy NL, Dadu R, Budde G, Malhotra M, Diersing J, Zafereo ME. A Proof-of-Concept Study for Detecting Circulating Tumor DNA in Rare Thyroid Cancers. Ann Oncol 33(suppl 7):S750-Ss757, 2022. e-Pub 2022.
- Hu MI, Subbiah V, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth LJ, Garralda E, Adkins D, Godbert Y, Ahn MJ, Cassier P, Cho BC, Lin CC, Barata T, Zalutskaya A, Scalori A, Brose MS. Updated ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Ann Oncol 33(suppl 7):S750-Ss757, 2022. e-Pub 2022.
- Hadoux J, Hu MI, Brose MS, Garralda E, Spitzweg C, Reguart N, Cao CD, Forster MD, Gordoa TA, Barata T, Scalori A, Zalutskaya A, Trask P, Subbiah V. Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive TC treated with pralsetinib in the ARROW trial. Endocrine Abstracts 84:PS3-15-134, 2022. e-Pub 2022.
- Maniakas A, Sullivan A, Busaidy N, Cabanillas M, Dadu R, Risher S, Graham P, Gross N, Grubbs E, Gunn GB, Hu M, Li X, Perrier N, Waguespack S, Wang J, Williams M, Zafereo M. Decreasing Indications for Postoperative Adjuvant Radiation Therapy in Locoregionally-Advanced Medullary Thyroid Cancer. Thyroid 31(S1), 2021. e-Pub 2021.
- Wirth LJ, Hu MI, Waguespack SG, Dosiou C, Ladenson P, Livhits MJ, Sadow PM, Krane J, Stack BC, Zafereo M, Ali SZ, Weitzman SP, Hao Y, Barbiarz J, Kennedy G, Kloos R. NTRK, RET, BRAF, and ALK fusions in thyroid fine-needle aspirates (FNAs). J Clin Oncol 39(suppl 15; abstr 6083), 2021. e-Pub 2021.
- Gordon M, Roszik J, Cabanillas ME, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Elamin YY, Cascone T, Byers LA, Blumenschein GR, Fossella FV, Naing A, Hong DS, Heymach J, Meric-Bernstram F, Subbiah V. Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials. J Clin Oncol 39(suppl 15; abstr 3117), 2021. e-Pub 2021.
- Jara M, Casteel KN, Afshar-Kharghan V, Subbiah V, Wing S, Hu MI. Paraneoplastic Eosinophilia: A Rare Finding in a Patient with Medullary Thyroid Carcinoma. J Endocrine Society 5(supplement 1):A896, 2021. e-Pub 2021.
Book Chapters
- Santillan, MR, Dadu, R, Gagel, RF, Grubbs, EG, Hu, MI. Systemic Therapies for Advanced Medullary Thyroid Carcinoma, 293-307, 2025.
- Hu MI, Santillan, Dadu, Gagel, Grubbs. Systemic Therapies for Advanced Medullary Thyroid Carcinoma. Springer Nature, 2024.
- Rich TA, Hu MI, Martin JW, Perrier ND, Waguespack SG. CDC73-related disorders. In: GeneReviews at GeneTests, 2023.
- Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. In: Curr Opin Endocrinol Diabetes Obes. 10th. McGraw-Hill, 744-65, 2021.
- Lee M, Waguespack SG, Graham PH, Hu MI, Zafereo ME. Syndromic Medullary Thyroid Carcinoma: MEN 2A and MEN 2B. In: Surgical and Medical Management of Diseases of the Thyroid and Parathyroid. Plural Publishing, Inc, 371-390, 2020.
- Dadu R, Hu MI. Medical Treatment Decision-Making for Advanced Medullary Thyroid Cancer. In: Thyroid Cancer: A Case-Based Approach. 2nd. Springer Nature, 2020.
- Hu MI, Grubbs EG, Sosa JA. Medullary Thyroid Carcinoma. In: Medical Management of Thyroid Disease. 3rd. CRC Press, 225-42, 2019.
- Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. CDC73-Related Disorders. In: GeneReviews. GeneReviews, 2018.
- Callejas LP, Ahn P, Holsinger FC, Hu MI. Thyroid and Parathyroid Cancers. In: Cancer Management Handbook. 17th. UBM Medica US, 2016.
- Hu, MI, Jimenez, C, Busaidy, NL, Habra, MA. Endocrinologic issues, 343-360, 2015.
- Jackson MA, Rich TA, Hu MI, Perrier ND, Waguespack SG. CDC73-related disorders. In: GeneReview, 2015.
- Dadu R, Gagel RF, Hu MI. Medical treatment decision-making for advanced, progressive medullary thyroid cancer. In: Thyroid Cancer: A Case-Based Textbook. Springer, 365-374, 2015.
- Hu MI, Jimenez C, Busaidy NL, Habra M. Long-term and late endocrine effects of cancer survivorship. In: Cancer Survivorship. 1st. Springer, 2014.
- Waguespack SG, Grubbs EG, Hu MI. Multiple endocrine neoplasia type 2. In: Clinical Genomics: Practical Applications in Adult Patient Care. 1st. McGraw Hill Education, 278-83, 2014.
- Dadu R, Ahn P, Holsinger FC, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 16th. UBM Medica, 2014.
- Dadu R, Ahn P, Holsinger FC, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 15th. UBM Medica, 2013.
- Hu MI, Jimenez C, Cote GJ, Gagel RF. Medullary thyroid carcinoma. In: The Thyroid. 10th. Lippincott Williams & Wilkins, 744-65, 2012.
- Thosani S, Ahn P, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 14th. CMP Medica, 2012.
- Alford E, Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 13th Edition. CMPMedica, 2011.
- Hu, MI, Gagel, RF. Multiple Endocrine Neoplasia Type 2, 2742-2758, 2010.
- Hu M, Gagel RF. Multiple endocrine neoplasia type 2. In: Endocrinology. 6th edition. Saunders, 2010.
- Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 12th Edition. CMPMedica, 51-70, 2010.
- Hu, MI, Sherman, SI. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery, 2nd edition, 85-103, 2009.
- Hu MI, Yeung SJ, Gagel RF. Endocrine paraneoplastic syndromes. In: Internal Medicine Care of Cancer Patients. BC Decker Inc; the Holland-Frei Series, 2009.
- Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont J. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 11th Edition. CMPMedica, 2009.
- Hu MI, Gagel RF. Calcitonin gene family of peptides. In: Principles of Bone Biology, 3rd edition, 2008.
- Fournier I, Hu MI, Waguespack S, Grubbs EG, Zafereo ME. Medullary Thyroid Carcinoma. 2nd. Publishing House.
Letters to the Editor
- Maniakas, A, Hu, MI, Gunn, GB, Zafereo, M. Reply to Letter to the Editor regarding “Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer”. Head and Neck 46: 1848-1849, 2024.
- Sarvestani, AL, Lambdin, J, Hu, MI, Cabanillas, ME, Waguespack, SG, Hernandez, J, Zafereo, M. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Annals of surgical oncology 31: 2202-2203, 2024.
- Gouda, MA, Hu, MI, Cabanillas, ME, Wu, J, Meric-Bernstam, F, Subbiah, V. Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors. Annals of Oncology 34: 946-948, 2023.
- Alsharif O, Panella T, Nodit L, Hu MI. ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma. Thyroid 33: 774-776, 2023.
Patient Reviews
CV information above last modified September 15, 2026